介入术后冠脉无复流的危险因素识别与药物治疗(4)
[14]Polimeni A，De Rosa S，Sabatino J，et al.Impact of intracoronary adenosine administration during primary PCI：A meta-analysis[J].Int J Cardiol，2016(203)：1032-1041.
[15]Nazir SA，McCann GP，Greenwood JP，et al.Strategies to attenuate micro-vascular obstruction during P-PCI： the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial[J].Eur Heart J，2016，37(24)：1910-1919.
[16]Feng C，Han B，Liu Y，et al.Effect of nicorandil administration on myocardial microcirculation during primary percutaneous coronary intervention in patients with acute myocardial infarction[J].Postepy Kardiol Interwencyjne，2018，14(1)：26-31.
, 百拇医药
[17]Yamada K，Isobe S，Ishii H，et al.Impacts of nicorandil on infarct myocardium in comparison with nitrate： assessed by cardiac magnetic resonance imaging[J].Heart & Vessels，2015，3(9)：1430-1437.
[18]齐琪，陈涛，牛竞辉，等.冠状动脉靶血管内注射尼可地尔对急性ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗术中无复流现象的预防效果研究[J].中国全科医学，2017，20(23)：2832-2837，2847.
[19]Soukoulis V，Boden WE，Smith SC，et al.Nonantithrombotic medical options in acute coronary syndromes： old agents and new lines on the horizon[J].Circ Res，2014，114(12)：1944-1958.
, 百拇医药
[20]Wang L，Cheng Z，Gu Y，et al.Short-Term Effects of Verapamil and Diltiazem in the Treatment of No Reflow Phenomenon：A Meta-Analysis of Randomized Controlled Trials[J].Biomed Res Int，2015(2015)：382086.
[21]Abdelaziz HK，Elkilany W，Khalid S，et al.Efficacy and safety of intracoronary verapamil versus sodium nitroprusside for the prevention of microvascular obstruction during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction[J].Coron Artery Dis，2017，28(1)：11-16.
, http://www.100md.com
[22]Abu Arab T，Rafik R，El Etriby，A.Efficacy and Safety of Local Intracoronary Drug Delivery in Treatment of No-Reflow Phenomenon： A Pilot Study[J].J Interv Cardiol，2016，29(5)：496-504.
[23]Kolh P，Windecker S，Alfonso F，et al.2014 ESC/EACTS Guidelines on myocardial revascularization： The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)[J].Eur Heart J，2014，46(4)：517-592.
, 百拇医药
[24]Ali-Hasan-Al-Saegh S，Mirhosseini SJ，Shahidzadeh A，et al.Appropriate bolus administration of glycoprotein Ⅱb/Ⅲa inhibitors for patients with acute coronary syndromes undergoing percutaneous coronary intervention：intracoronary or intravenous？ A comprehensive and updated meta-analysis and systematic review[J].Kardiol Pol，2016，74(2)：104-118.
[25]Sun B，Liu Z，Yin H，et al.Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes：A meta-analysis of randomized controlled trials[J].Medicine (Baltimore)，2017， 96(40)：e8223.
, 百拇医药
[26]Aksu T，Guler TE，Colak A，et al.Intracoronary epinephrine in the treatment ofrefractory no-reflow after primary percutaneous coronary intervention： aretrospective study[J].BMC Cardiovascular Disorders，2015，15(1)：10.
[27]Zhang CJ，Deng YZ，Lei YH，et al.The mechanism of exogenous adiponectin in theprevention of no-reflow phenomenon in type 2 diabetic patients with acutemyocardial infarction during PCI treatment.[J].Eur Rev Med PharmacolSci，2018，22(7)：2169-2174.
收稿日期：2018-10-29;修回日期：2018-11-13
編辑/肖婷婷, http://www.100md.com(杨国锋 钱朝庆 白文伟)
[15]Nazir SA，McCann GP，Greenwood JP，et al.Strategies to attenuate micro-vascular obstruction during P-PCI： the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial[J].Eur Heart J，2016，37(24)：1910-1919.
[16]Feng C，Han B，Liu Y，et al.Effect of nicorandil administration on myocardial microcirculation during primary percutaneous coronary intervention in patients with acute myocardial infarction[J].Postepy Kardiol Interwencyjne，2018，14(1)：26-31.
, 百拇医药
[17]Yamada K，Isobe S，Ishii H，et al.Impacts of nicorandil on infarct myocardium in comparison with nitrate： assessed by cardiac magnetic resonance imaging[J].Heart & Vessels，2015，3(9)：1430-1437.
[18]齐琪，陈涛，牛竞辉，等.冠状动脉靶血管内注射尼可地尔对急性ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗术中无复流现象的预防效果研究[J].中国全科医学，2017，20(23)：2832-2837，2847.
[19]Soukoulis V，Boden WE，Smith SC，et al.Nonantithrombotic medical options in acute coronary syndromes： old agents and new lines on the horizon[J].Circ Res，2014，114(12)：1944-1958.
, 百拇医药
[20]Wang L，Cheng Z，Gu Y，et al.Short-Term Effects of Verapamil and Diltiazem in the Treatment of No Reflow Phenomenon：A Meta-Analysis of Randomized Controlled Trials[J].Biomed Res Int，2015(2015)：382086.
[21]Abdelaziz HK，Elkilany W，Khalid S，et al.Efficacy and safety of intracoronary verapamil versus sodium nitroprusside for the prevention of microvascular obstruction during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction[J].Coron Artery Dis，2017，28(1)：11-16.
, http://www.100md.com
[22]Abu Arab T，Rafik R，El Etriby，A.Efficacy and Safety of Local Intracoronary Drug Delivery in Treatment of No-Reflow Phenomenon： A Pilot Study[J].J Interv Cardiol，2016，29(5)：496-504.
[23]Kolh P，Windecker S，Alfonso F，et al.2014 ESC/EACTS Guidelines on myocardial revascularization： The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)[J].Eur Heart J，2014，46(4)：517-592.
, 百拇医药
[24]Ali-Hasan-Al-Saegh S，Mirhosseini SJ，Shahidzadeh A，et al.Appropriate bolus administration of glycoprotein Ⅱb/Ⅲa inhibitors for patients with acute coronary syndromes undergoing percutaneous coronary intervention：intracoronary or intravenous？ A comprehensive and updated meta-analysis and systematic review[J].Kardiol Pol，2016，74(2)：104-118.
[25]Sun B，Liu Z，Yin H，et al.Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes：A meta-analysis of randomized controlled trials[J].Medicine (Baltimore)，2017， 96(40)：e8223.
, 百拇医药
[26]Aksu T，Guler TE，Colak A，et al.Intracoronary epinephrine in the treatment ofrefractory no-reflow after primary percutaneous coronary intervention： aretrospective study[J].BMC Cardiovascular Disorders，2015，15(1)：10.
[27]Zhang CJ，Deng YZ，Lei YH，et al.The mechanism of exogenous adiponectin in theprevention of no-reflow phenomenon in type 2 diabetic patients with acutemyocardial infarction during PCI treatment.[J].Eur Rev Med PharmacolSci，2018，22(7)：2169-2174.
收稿日期：2018-10-29;修回日期：2018-11-13
編辑/肖婷婷, http://www.100md.com(杨国锋 钱朝庆 白文伟)